These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34050749)

  • 1. Impact of rapid infliximab infusions on access at a large academic tertiary medical center.
    Pusateri A; Hatcher A; Patel N; Lehman J; Hinton A; Afzali A
    Am J Health Syst Pharm; 2021 Nov; 78(22):2046-2052. PubMed ID: 34050749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: rapid infliximab infusions are safe.
    Neef HC; Riebschleger MP; Adler J
    Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
    Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
    Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of infliximab in children with IBD: the experience of an academic center in WV.
    Northcutt M; Al-Subu A; Bella B; Elitsur Y
    W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
    Hilley P; Wong D; Ma R; Peterson A; De Cruz P
    Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
    Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease.
    Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL
    J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
    Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
    Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.